Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 at 10:00 a.m. ET in New York. The company's innovations focus on controlling gene expression with a clinical-stage pipeline that includes treatments for higher-risk myelodysplastic syndrome, acute myeloid leukemia, and acute promyelocytic leukemia. A live webcast will be available on their website, with an archived replay accessible for 30 days post-event.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference. Management will also be available for one-on-one meetings. Details are as follows:

H.C. Wainwright 24th Annual Global Investment Conference

Date: Wednesday, September 14
Time: 10:00 a.m. ET
Location: The Lotte New York Palace, 455 Madison Avenue, New York, NY

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005019/en/

Media:

Brittany Leigh, Ph.D.

LifeSci Communications, LLC

+1-813-767-7801

bleigh@lifescicomms.com

Investor:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

When will Syros Pharmaceuticals present at the H.C. Wainwright conference?

Syros Pharmaceuticals will present on September 14 at 10:00 a.m. ET.

Where is the H.C. Wainwright conference located?

The conference will be held at The Lotte New York Palace, 455 Madison Avenue, New York, NY.

Who is the CEO of Syros Pharmaceuticals?

The CEO of Syros Pharmaceuticals is Nancy Simonian, M.D.

How can I watch the Syros Pharmaceuticals presentation?

The presentation will be available via a live webcast on the Syros website.

What key projects is Syros Pharmaceuticals working on?

Syros is developing treatments for myelodysplastic syndrome, acute myeloid leukemia, and acute promyelocytic leukemia.